Clinical Trials | February 17, 2026
Roche’s Gazyva hits major milestone in rare kidney disease
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Duvakitug was well tolerated and safety was consistent with the induction study
Iberdomide has the potential to be the first approved CELMoD agent
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Subscribe To Our Newsletter & Stay Updated
